UBI.AX | Universal Biosensors, Inc.

Market Cap (In AUD)

37.25 Million

Revenue (In AUD)

6.63 Million

Net Income (In AUD)

-6.74 Million

Avg. Volume

78.52 Thousand

Company Profile

Sector: Healthcare
Industry: Medical - Devices
CEO: Mr. John Stewart Sharman B Ec, BECON, C.A., CA, M.App.Fin
Employee Count: -
Website: https://www.universalbiosensors.com
Ipo Date: 2006-12-12
Details: Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company primarily in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips; and distributes Siemens' Xprecia Stride Coagulation Analyzer, a test used to monitor the effect of the anticoagulant therapy warfarin. The company also manufactures and distributes Sentia SO2 test strips; and distributes Sentia Analyzer for the use in measurement of free SO2 levels in post-fermentation wine. In addition, it offers non-diagnostic laboratory services and performs coagulation testing services. The company has a license agreement with LifeScan Global Corporation to develop a biosensor strip and a meter to be used for the detection and monitoring of diabetes in animals. Universal Biosensors, Inc. was incorporated in 2001 and is headquartered in Rowville, Australia.